Nausea is common during the first few weeks and typically diminishes over time
GLP-1 ID takes this model even further by introducing a structured system for weekly dose adjustments, tailored to each patient's biology, symptoms, and goals
[2] [3] Similarly, in the SURMOUNT trials for weight management, Zepbound's label reports gastrointestinal events as the most common adverse reactions, with nausea (24-30%), diarrhea (18-23%), vomiting (8-12%), and constipation (11-17%) occurring at somewhat higher rates than in diabetes trials
Combined with adequate protein intake and resistance training, glycine in a compounded tirzepatide formulation represents a rational approach to improving the quality of weight lost
Tirzepatide is a dual agonist targeting GLP-1 and GIP receptors